Eventi SITeCS

Ipercolesterolemia familiare: diagnosi e terapia

Milano, 11 Dicembre 2019

[continua a leggere]

Dyslipidaemias: present and future approaches to pharmacological intervention

Sorrento (Na), 9-10, November 2019
[continua a leggere]

ECM FAD

Ipercolesterolemia Familiare Omozigote: approcci diagnostici e terapeutici

[continua a leggere]

Il ruolo del controllo della colesterolemia nella prevenzione primaria e secondaria delle malattie cardiovascolari

[continua a leggere]

Area Soci

Newsletter

Per essere informati sulle novità di SITeCS iscrivetevi alla nostra newsletter inserendo il vostro indirizzo di posta elettronica

Linee Guida Consensus

Bookmark and Share

OMEGA 3 FATTY ACIDS AND CARDIOVASCULAR DISEASE

Proceedings from the SITeCS Meeting
Atheroscler Suppl. 2013;14


 

The Italian Society for Experimental and Clinical Therapeutics holds a yearly national meeting. This year’s meeting was held in Brescia at the beginning of March. One of the characteristics of the meeting is to address in a timely manner topics that are relevant to cardiovascular therapy. One of these topics, identified by the scientific committee, was the use of polyunsaturated fatty acids of the omega 3 series in cardiovascular diseases. The round table resulted in an indepth discussion on the role of these fatty acids in medicine, as some data suggested that perhaps the currently accepted role for this therapy should be reassessed. This derives from some recent trials and a meta-analysis published from 2010 to 2012. The focus of the symposium held was to address this topic and to provide a new meta-analysis on clinical trials using omega 3 fatty acids as drugs, not as dietary supplements, at a defined dose. In addition, the data on the biochemical background and the effect on plasma lipids and lipoproteins were reviewed and discussed. The results suggest that omega 3 fatty acids have the potential for providing a cardiovascular benefit to high risk patients in addition to a role in controlling plasma triglycerides in dyslipidaemias. In addition, the anti-inflammatory role of omega 3 remains to be fully elucidated and clinical mechanistic studies are urgently needed to substantiate these findings.

 

 


Omega 3 Fatty Acids and Cardiovascular Disease
Atheroscler Suppl. 2013;14 (Sito Elsevier)

• Atheroscler Suppl. 2013;14:229
• Atheroscler Suppl. 2013;14:230-236
• Atheroscler Suppl. 2013;14:237-242
• Atheroscler Suppl. 2013;14:243-251


Introduction
(98KB) (A disposizione dei soci)
Alberico L. Catapano
Atheroscler Suppl. 2013;14:229 (Sito Elsevier)


Clinical pharmacology of n-3 polyunsaturated fatty acids: non-lipidic metabolic and hemodynamic effects in human patients (152KB) (A disposizione dei soci)
Franca Marangoni, Andrea Poli
Atheroscler Suppl. 2013;14:230-236 (Sito Elsevier)


Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia (139KB) (A disposizione dei soci)
Angela Pirillo, Alberico L. Catapano
Atheroscler Suppl. 2013;14:237-242 (Sito Elsevier)


Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials (466KB) (A disposizione dei soci)
Manuela Casula, Davide Soranna, Alberico L. Catapano, Giovanni Corrao
Atheroscler Suppl. 2013;14:243-251 (Sito Elsevier)